Background
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening syndrome comprising severe skin eruption, fever, eosinophilia, lymphadenopathy, and involvement of internal organs [1] [2] [3] .
Vancomycin and teicoplanin are glycopeptides currently used for the treatment of infections caused by invasive beta-lactam-resistant Gram-positive organisms such as methicillin-resistant Staphylococcus aureus (MRSA). Teicoplanin is not inferior to vancomycin with regard to efficacy and is associated with fewer adverse events than vancomycin, including events requiring the discontinuation of treatment, nephrotoxicity, and red man syndrome [4] .
Herein, we describe a case of DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration. In the diagnosis of adverse drug reactions that developed in our patient, we applied 2 scoring systems: the Naranjo Probability Scale (NPS) [5] and the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system [6, 7] .
Case Report
A 79-year-old male was admitted to our hospital for the treatment of injuries incurred in a traffic accident. He had no significant history of tuberculosis, HIV infection, diabetes mellitus, hypertension, hyperlipidemia, hepatitis, or disease in any major organ. He had not been taking any medication and had not experienced allergies to drugs or food previously.
Osteosynthesis for femur fracture and debridement for thighskin necrosis were undertaken on day 13 and day 21 of hospital admission (i.e., hospital day (HD)13 and HD21), respectively). Then, MRSA was detected from a wound in a skin defect on HD52. Figure 1 shows his clinical manifestations, laboratory data, and medication history. On HD54, serum level of C-reactive protein was 14.63 mg/dL. On HD59, vancomycin treatment (1.0 g every 12 h, i.v.) was initiated. On HD60, MRSA was cultured from blood. He developed upper-limb erythema and persistent fever (³38°C) on HD77 (day 18 of vancomycin therapy) and on HD79 (day 20 of vancomycin therapy), respectively. Renal and liver function remained within normal limits. However, Table 1 . Classification of adverse reactions according to the Naranjo Probability Scale. Bold cells are positive finding in our case. Total scores in our case for vancomycin and teicoplanin were 5 and 7, respectively.
Final scores 1-4 = Possible, 5-8 = Probable, and >9 = Definite case.
eosinophilia (grade 1:>700/mm 3 ) developed on day 29 of vancomycin therapy. On HD88, the patient required supplemental oxygen and developed an extensive skin rash with eyelid edema. According to the NPS, we categorized these adverse reactions related to vancomycin as "probable," with a score of 5.
Vancomycin-induced hypersensitivity syndrome was suspected, so vancomycin therapy was discontinued and teicoplanin treatment (400 mg every 12 h, i.v.) was initiated on HD88. On HD94, radiography of the chest showed a diffuse "ground glass" shadow (Figure 2A ). Computed tomography of the lungs revealed diffuse pneumonic infiltrates ( Figure 2B ). Oxygen and prednisolone (50 mg/day, p.o.) for hypersensitivity syndrome with lung dysfunction (interstitial pneumonitis) were administrated on HD88-106 and on HD94-99, respectively. As a result, hypersensitivity syndrome with interstitial pneumonitis was improved temporarily. However, the patient again developed fever (³38°C) and upper-limb erythema on day 12 and day 15 of , respectively. According to the NPS, we categorized these adverse reactions related to teicoplanin as "probable," with a score of 7. Teicoplanin-induced hypersensitivity syndrome was suspected, so teicoplanin therapy was discontinued and linezolid treatment (600 mg every 12 h, i.v.) was initiated on HD104. After withdrawal of teicoplanin therapy, fever and rash disappeared on HD106.
After reviewing the time span between medication administration and symptom onset, we strongly suspected cross-reactivity between these 2 glycopeptide antibiotics, although we could not completely exclude the possibility of reappearance of DRESS with vancomycin use. When using the RegiSCAR scoring, we categorized DRESS syndrome related to vancomycin and teicoplanin as "probable," with a score of 4. Tables 1  and 2 show the detailed application of the NPS and RegiSCAR scoring systems for our patient, respectively.
Discussion
DRESS syndrome is an acute drug-induced hypersensitivity reaction. Estimated incidence of DRESS syndrome ranges from 1 in 1000 to 1 in 10 000 drug exposures [3] . Recognition of DRESS syndrome is important because mortality can occur in £10% of patients. Teicoplanin-associated DRESS syndrome or drug-induced hypersensitivity syndrome (DIHS) has rarely been reported in the literature [8] [9] [10] [11] [12] [13] . Table 3 shows the clinical characteristics of our patient and other reported cases of teicoplanin-induced DRESS/DIHS by cross-reaction between vancomycin and teicoplanin. In our patient, rash, eosinophilia, and lung dysfunction (interstitial pneumonitis) appeared after vancomycin administration. These symptoms were improved temporarily by withdrawal of vancomycin and administration of corticosteroid, but exacerbated by teicoplanin administration. The symptoms disappeared after discontinuation of teicoplanin. Based on comprehensive assessment of the overall clinical course, we judged that DRESS syndrome with rash, eosinophilia, and interstitial pneumonitis was induced by crossreactivity between vancomycin and subsequent teicoplanin administration. To define DRESS syndrome more accurately, the RegiSCAR scoring system has been recently developed [6, 7] . By using the RegiSCAR scoring system, we categorized DRESS syndrome related to vancomycin and teicoplanin in our patient as probable (score=4). We report, for the first time, a case of DRESS syndrome defined using the RegiSCAR scoring system caused by cross-reactivity between vancomycin and subsequent teicoplanin administration.
Pulmonary involvement was reported in 2 of the 8 patients listed in Table 3 . This symptom is of particular interest because it was reported only in 5% of 172 cases of DRESS syndrome [3] . In addition, neutropenia was reported in 4 of the 11 patients listed in Table 3 . Based on a retrospective review by Hung and colleagues, 12 of 109 patients with vancomycin-induced fever and/or rash were reported to subsequently develop teicoplanin-induced fever or rash after switching to teicoplanin. However, 4 of the 8 patients with vancomycin-induced neutropenia subsequently developed neutropenia after switching to teicoplanin [14] . Vancomycin-induced neutropenia should therefore be considered as a contraindication for switching from vancomycin to teicoplanin.
The pathogenesis of DRESS syndrome remains obscure, with a number of mechanisms implicated in its development [3] . First, DRESS is associated with the reactivation of HHV-6 and other herpes viruses. The serology of these viruses should be determined in DRESS patients (although virus reactivation was not found in our case). Second, the formation of reactive metabolites is hypothesized to play a role in the pathogenesis of DRESS syndrome. Because neither vancomycin nor teicoplanin is metabolized in the liver, reactive metabolites could not have contributed to the pathogenesis of DRESS in our case. New options for the treatment of severe DRESS have to be considered for sequential pathogenetic mechanisms. N-acetylcysteine potentially neutralizes drug-derived reactive metabolites responsible for protein adduct formation and specific T cell stimulation, and replenishes the glutathione stores to counterbalance oxidative stress. Prednisone may inhibit lymphoproliferation, while valganciclovir can prevent complications related to HHV-6 reactivation. Therefore, combination therapy using N-acetylcysteine, prednisone, and valganciclovir as a treatment option for DRESS has been proposed [15] . Finally, it seems clear that genetic background plays a role in susceptibility to rare diseases or drug reactions. More than 50% of HLA-B5701-positive individuals develop hypersensitivity to abacavir. Because the HLA systems are a component of the acquired immune response, HLA testing should be performed in every case of DRESS to collect data indicative of possible associations.
Conclusions
Clinicians should be aware that DRESS syndrome can be induced by cross-reactivity between vancomycin and teicoplanin. The management of DRESS syndrome is immediate withdrawal of the suspected offending medication and administration of a corticosteroid. Moling et al. recently suggested adding N-acetylcysteine and valganciclovir for a better management of DRESS syndrome and its complications (e.g., CMV infection) to [15] .
